Temedica's CEO, Gloria Seibert, is listed on Manager Magazin's "Top 100 most influential Women"
Temedica is thrilled to announce that our very own CEO, Gloria Seibert, has been recognised as one of the Top 100 most influential Women in the German economy.
This prestigious list, compiled by the German business magazine Manager Magazin, recognises the outstanding achievements and contributions of women in the business world. We are incredibly proud of Gloria's inclusion on this list, which is a testament to her leadership and vision in building Temedica into a leading digital health insights company.
As CEO, Gloria has fundamentally rethought the way health data should be used. Rather than allowing data to live in silos, Gloria has built a collaborative ecosystem that includes all healthcare stakeholders. Under her guidance, Temedica has developed a range of digital health solutions that leverage this interconnected ecosystem to improve patient outcomes and reduce the burden on healthcare systems. By bringing together patients, healthcare providers, pharmaceutical companies, and other stakeholders, Gloria has created a truly holistic approach to healthcare that is driving positive change in the industry.
Gloria's recognition on the Top 100 list is a reflection of her dedication to driving positive change in the healthcare industry. We are proud to have such a dynamic and inspiring leader at the helm of our company, and we look forward to continuing to make a positive impact under her guidance.
Congratulations, Gloria, on this well-deserved recognition!
The full list of the Top 100 most influential Women in the German Economy can be found here.
The editorial on Gloria Seibert can be found here. Please note, both articles are in German and are gated for Manager Magazin subscribers.
Temedica is a health insights company based in Munich. Since 2016, Temedica has been operating Europe's leading ecosystem for real world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.
Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit https://temedica.com/.
For more information, please contact:
Phone: +49 (0) 175 4310301